Origin

Executive Summary

Origin Life Sciences is a clinical-stage biotechnology company developing the IonoJet™, a proprietary high-energy plasma device that generates and delivers a nitric oxide (NO) plasma stream for therapeutic applications. The company's primary focus is on treating chronic wounds and skin/soft tissue infections, leveraging nitric oxide's antimicrobial, anti-inflammatory, and tissue-regenerative properties. Founded in 2018 and headquartered in San Francisco, Origin aims to address the significant unmet need in wound care, where current treatments are often inadequate against biofilm-associated infections and impaired healing. As a private company with no disclosed funding or valuation, Origin is in early clinical development, and its technology offers a novel non-invasive approach to a large and growing market.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Clinical Trial Results for Chronic Wounds40% success
• Q2 2026FDA Pre-IND or Investigational Device Exemption (IDE) Meeting70% success